[go: up one dir, main page]

AU2018378804B2 - Dosing regimens for the mobilization of hematopoietic stem and progenitor cells - Google Patents

Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Info

Publication number
AU2018378804B2
AU2018378804B2 AU2018378804A AU2018378804A AU2018378804B2 AU 2018378804 B2 AU2018378804 B2 AU 2018378804B2 AU 2018378804 A AU2018378804 A AU 2018378804A AU 2018378804 A AU2018378804 A AU 2018378804A AU 2018378804 B2 AU2018378804 B2 AU 2018378804B2
Authority
AU
Australia
Prior art keywords
cells
fold
per day
donor
cd45ra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018378804A
Other languages
English (en)
Other versions
AU2018378804A1 (en
Inventor
Anthony Boitano
Michael P. Cooke
Patrick C. Falahee
Kevin A. Goncalves
Dwight Morrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ensoma Inc
Original Assignee
Ensoma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/834,017 external-priority patent/US10058573B1/en
Application filed by Ensoma Inc filed Critical Ensoma Inc
Publication of AU2018378804A1 publication Critical patent/AU2018378804A1/en
Assigned to ENSOMA, INC. reassignment ENSOMA, INC. Request for Assignment Assignors: Magenta Therapeutics, Inc.
Application granted granted Critical
Publication of AU2018378804B2 publication Critical patent/AU2018378804B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
AU2018378804A 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells Active AU2018378804B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US15/834,017 2017-12-06
US15/834,017 US10058573B1 (en) 2017-12-06 2017-12-06 Dosing regimens for the mobilization of hematopoietic stem cells
US201762596056P 2017-12-07 2017-12-07
US62/596,056 2017-12-07
US16/101,676 US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells
US16/101,676 2018-08-13
US201862753656P 2018-10-31 2018-10-31
US62/753,656 2018-10-31
US201862773954P 2018-11-30 2018-11-30
US62/773,954 2018-11-30
PCT/US2018/064335 WO2019113375A2 (fr) 2017-12-06 2018-12-06 Régimes posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques

Publications (2)

Publication Number Publication Date
AU2018378804A1 AU2018378804A1 (en) 2020-06-11
AU2018378804B2 true AU2018378804B2 (en) 2025-10-02

Family

ID=66749948

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018378804A Active AU2018378804B2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Country Status (12)

Country Link
EP (1) EP3720494A2 (fr)
JP (2) JP2021505172A (fr)
KR (1) KR20200096942A (fr)
CN (1) CN111712262A (fr)
AU (1) AU2018378804B2 (fr)
BR (1) BR112020011186A2 (fr)
CA (1) CA3083783A1 (fr)
CO (1) CO2020007275A2 (fr)
IL (2) IL275077B2 (fr)
MX (2) MX2020005878A (fr)
SG (1) SG11202004913TA (fr)
WO (1) WO2019113375A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP4051298A1 (fr) * 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation de cellules souches et progénitrices hématopoïétiques
CA3176979A1 (fr) * 2020-04-27 2021-11-04 Anthony Boitano Methodes et compositions pour la transduction de cellules souches et progenitrices hematopoietiques in vivo
WO2022197776A1 (fr) * 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Schémas posologiques pour la mobilisation des cellules souches hématopoïétiques en vue d'une greffe de cellules souches chez les patients atteints de myélome multiple
KR20250023521A (ko) * 2022-06-10 2025-02-18 주식회사 지피씨알 Gpcr 억제제 및 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000333A1 (fr) * 2003-06-05 2005-01-06 Anormed Inc. Procedes de mobilisation de cellules progenitrices/souches
US20060035829A1 (en) * 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2007047882A2 (fr) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combinaison d'un antagoniste cxcr4 et d'un morphogene pour l'accroissement de l'angiogenese
WO2008017025A2 (fr) * 2006-08-02 2008-02-07 Genzyme Corporation Thérapie combinée
WO2008019371A1 (fr) * 2006-08-07 2008-02-14 Genzyme Corporation Thérapie combinée
WO2017147610A1 (fr) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Cellules souches hématopoïétiques à haut potentiel de prise de greffe

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5233044A (en) 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
ATE253637T1 (de) 1993-06-08 2003-11-15 Smithkline Beecham Corp Methoden zur erhöhung der biologischen aktivität von chemokinen
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
DK0909176T3 (da) 1997-02-11 2003-02-17 Mallinckrodt Inc Reaktor og fremgangsmåde til fastfasepeptidsyntese
CA2731416A1 (fr) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Applications therapeutiques et diagnostiques basees sur le role du gene cxcr-4 dans l'oncogenese
MXPA01009674A (es) 1999-03-24 2003-07-21 Anormed Inc Compuestos heterociclicos que se unen a receptores de quimiocina.
AU2334301A (en) 1999-12-17 2001-06-25 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AU2001258110B2 (en) 2000-05-09 2006-10-19 British Canadian Biosciences Corp. Cxcr4 antagonist treatment of hematopoietic cells
US20040131585A1 (en) 2000-06-05 2004-07-08 Silviu Itescu Identification and use og human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
MXPA04000982A (es) * 2001-07-31 2004-04-20 Anormed Inc Metodos para movilizar celulas progenitoras/madre.
CA2456977C (fr) 2001-08-16 2011-06-07 The Trustees Of The University Of Pennsylvania Synthese et utilisation de reactifs pour ameliorer la lipofection d'adn et/ou les therapies par medicaments et promedicaments a liberation lente
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
EP1648914A4 (fr) 2003-07-31 2009-12-16 Regulus Therapeutics Inc Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
AU2006262020B8 (en) 2005-06-24 2011-02-17 Recombinetics, Inc. Using cytosine deaminases to diminish retroelement transfer from pigs to humans
CA3055968A1 (fr) 2005-10-18 2007-04-26 Duke University Meganucleases concues rationnellement possedant une specificite sequence modifiee et une affinite de liaison pour l'adn
EP1995316A1 (fr) 2007-05-25 2008-11-26 Qiagen GmbH Procédé de purification de cellules préservant lesdites cellules, obtention de cellules et transfection de cellules
EP2009095A1 (fr) 2007-06-28 2008-12-31 Innovalor AG Procédé de génération de céllules sensibles au glucose
EP3578646A3 (fr) 2007-10-31 2020-03-18 Precision Biosciences, Inc. Méganucléases monocaténaires concues rationnellement contenant des séquences de reconnaissance non palindromiques
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
EP2270025A1 (fr) 2009-06-29 2011-01-05 Centre National pour la Recherche Scientifique (CNRS) Synthèse de peptide en phase solide d'alcools peptidiques
WO2011100505A2 (fr) 2010-02-11 2011-08-18 Recombinetics, Inc. Procédés et matériaux pour la production d'artiodactyles transgéniques
EA201391234A1 (ru) 2011-02-25 2014-05-30 Рикомбинетикс, Инк. Генетически модифицированные животные и способы их получения
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014113439A1 (fr) * 2013-01-15 2014-07-24 Ohio State Innovation Foundation Méthodes de mobilisation de cellules souches hématopoïétiques
KR20160023638A (ko) * 2013-02-28 2016-03-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 이동하기 위한 방법 및 조성물
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
WO2018085574A2 (fr) * 2016-11-02 2018-05-11 Washington University Compositions comprenant un inhibiteur d'intégrine et des agents qui interagissent avec une chimiokine et leurs procédés d'utilisation
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000333A1 (fr) * 2003-06-05 2005-01-06 Anormed Inc. Procedes de mobilisation de cellules progenitrices/souches
US20060035829A1 (en) * 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2007047882A2 (fr) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combinaison d'un antagoniste cxcr4 et d'un morphogene pour l'accroissement de l'angiogenese
WO2008017025A2 (fr) * 2006-08-02 2008-02-07 Genzyme Corporation Thérapie combinée
WO2008019371A1 (fr) * 2006-08-07 2008-02-14 Genzyme Corporation Thérapie combinée
WO2017147610A1 (fr) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Cellules souches hématopoïétiques à haut potentiel de prise de greffe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PELUS, L.M. et al., 'The Combination of AMD3100 Plus GROβ Rapidly Mobilizes Hematopoietic Stem Cells with Enhanced Homing, Adhesion and Survival Properties, BLOOD, 2008, Vol. 112, No. 11: 71 *
PELUS, L.M. et al., 'The CXCR4 antagonist AMD3100 and the CXCR2 agonist GROβ synergistically mobilize hematopoetic stem cells (HSC) with short and long term repopulating activity', BLOOD, 2006, Vol. 108, No. 11: 339 *

Also Published As

Publication number Publication date
MX2020005878A (es) 2020-10-07
IL315735A (en) 2024-11-01
JP2024023226A (ja) 2024-02-21
EP3720494A2 (fr) 2020-10-14
BR112020011186A2 (pt) 2020-11-17
WO2019113375A3 (fr) 2019-07-18
CO2020007275A2 (es) 2020-07-31
WO2019113375A2 (fr) 2019-06-13
IL275077B2 (en) 2025-02-01
SG11202004913TA (en) 2020-06-29
IL275077A (en) 2020-07-30
IL275077B1 (en) 2024-10-01
JP2021505172A (ja) 2021-02-18
CA3083783A1 (fr) 2019-06-13
MX2024004652A (es) 2024-05-07
CN111712262A (zh) 2020-09-25
KR20200096942A (ko) 2020-08-14
AU2018378804A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
US20250295698A1 (en) Dosing regimens for the mobilization of hematopoietic stem cells
AU2018378804B2 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20250032549A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
JP7412341B2 (ja) 造血幹細胞および前駆細胞の増幅のための組成物および方法
US11260079B2 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20190343885A1 (en) Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
US20220401481A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20230330185A1 (en) Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
US20240189387A1 (en) Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
EP3735412B1 (fr) Compositions et procédés de multiplication de cellules souches et progénetrices hemapoiétiques et la traitement des désordres métaboliques.
US20230414565A1 (en) Compositions and methods for treating hematological malignancies
US20210379113A1 (en) Methods for hematopoietic stem and progenitor cell transplant therapy

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ENSOMA, INC.

Free format text: FORMER APPLICANT(S): MAGENTA THERAPEUTICS, INC.